FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 328:1163-1165 April 22, 1993 Number 16 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Strains of human immunodeficiency virus type 1 (HIV-1) with reduced sensitivity to zidovudine have been isolated from patients treated with this drug for six months or more¹. Resistance to zidovudine is associated with late-stage disease, low CD4 lymphocyte counts, longer antiretroviral therapy, and specific mutations in the reverse transcriptase gene of HIV-1^2,3. The clinical importance of infections with resistant HIV-1 isolates is not well understood. We describe a patient with symptomatic HIV-1 infection who had primary infection with a virus resistant to zidovudine, according to both phenotypic and genotypic analyses.

Case Report

The patient was a 20-year-old homosexual man who . . . [Full Text of this Article]

Methods

Results

Discussion

Source Information

From the Departments of Laboratory Medicine and Pathology, Medicine, and Pediatrics, University of Minnesota Medical School, and the AIDS Clinical Trials Unit, Minneapolis (A.E., K.J.S., H.H.B.); the Naval Medical Research Institute and Division of Retrovirology, Walter Reed Army Institute of Research, Washington, D.(D.L.M.); the Henry M. Jackson Foundation Research Laboratory, Rockville, Md. (F.E.M.); Group Health Inc., Riverside Medical Center, Minneapolis (D.G.S.); and St. Paul Ramsey Medical Center, St. Paul, Minn. (K.H.). Presented at the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, Calif., October 13, 1992.

Address reprint requests to Dr. Balfour at Box 437 UMHC, Harvard St. at E. River Rd., Minneapolis, MN 55455.

References

Related Letters:

Primary Infection with Zidovudine-Resistant HIV
Hermans P., Sprecher S., Clumeck N., Masquelier B., Lemoigne E., Pellegrin I., Douard D., Sandler B., Fleury H. J.A., Erice A., Balfour H. H.
Extract | Full Text  
N Engl J Med 1993; 329:1123-1124, Oct 7, 1993. Correspondence

This article has been cited by other articles:

• Sagir, A., Oette, M., Kaiser, R., Daumer, M., Fatkenheuer, G., Rockstroh, J. K., Knechten, H., Schmutz, G., Hower, M., Emmelkamp, J., Pfister, H., Haussinger, D., on behalf of the RESINA Study Team, (2007). Trends of prevalence of primary HIV drug resistance in Germany. J Antimicrob Chemother 60: 843-848 [Abstract] [Full Text]  
• Taiwo, B. O., Murphy, R. (2007). Transmitted Resistance: An Overview and Its Potential Relevance to the Management of HIV-Infected Persons in Resource-Limited Settings. J Int Assoc Physicians AIDS Care (Chic Ill) 6: 188-197 [Abstract]  
• Booth, C. L., Geretti, A. M. (2007). Prevalence and determinants of transmitted antiretroviral drug resistance in HIV-1 infection. J Antimicrob Chemother 59: 1047-1056 [Abstract] [Full Text]  
• de Mendoza, C., Rodriguez, C., Garcia, F., Eiros, J. M., Ruiz, L., Caballero, E., Aguilera, A., Leiva, P., Colomina, J., Gutierrez, F., del Romero, J., Aguero, J., Soriano, V., on behalf of the Spanish HIV Seroconverter Study G, (2007). Prevalence of X4 tropic viruses in patients recently infected with HIV-1 and lack of association with transmission of drug resistance. J Antimicrob Chemother 59: 698-704 [Abstract] [Full Text]  
• Booth, C. L., Garcia-Diaz, A. M., Youle, M. S., Johnson, M. A., Phillips, A., Geretti, A. M. (2007). Prevalence and predictors of antiretroviral drug resistance in newly diagnosed HIV-1 infection. J Antimicrob Chemother 59: 517-524 [Abstract] [Full Text]  
• Garcia-Lerma, J. G., MacInnes, H., Bennett, D., Weinstock, H., Heneine, W. (2004). Transmitted Human Immunodeficiency Virus Type 1 Carrying the D67N or K219Q/E Mutation Evolves Rapidly to Zidovudine Resistance In Vitro and Shows a High Replicative Fitness in the Presence of Zidovudine. J. Virol. 78: 7545-7552 [Abstract] [Full Text]  
• Clavel, F., Hance, A. J. (2004). HIV Drug Resistance. NEJM 350: 1023-1035 [Full Text]  
• Havens, P. L., Committee on Pediatric AIDS, (2003). Postexposure Prophylaxis in Children and Adolescents for Nonoccupational Exposure to Human Immunodeficiency Virus. Pediatrics 111: 1475-1489 [Abstract] [Full Text]  
• Little, S. J., Holte, S., Routy, J.-P., Daar, E. S., Markowitz, M., Collier, A. C., Koup, R. A., Mellors, J. W., Connick, E., Conway, B., Kilby, M., Wang, L., Whitcomb, J. M., Hellmann, N. S., Richman, D. D. (2002). Antiretroviral-Drug Resistance among Patients Recently Infected with HIV. NEJM 347: 385-394 [Abstract] [Full Text]  
• Kuritzkes, D. R. (2001). A fossil record of zidovudine resistance in transmitted isolates of HIV-1. Proc. Natl. Acad. Sci. USA 98: 13485-13487 [Full Text]  
• Garcia-Lerma, J. G., Nidtha, S., Blumoff, K., Weinstock, H., Heneine, W. (2001). Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons. Proc. Natl. Acad. Sci. USA 10.1073/pnas.241300698v1 [Abstract] [Full Text]  
• Sharma, R. (2000). Antiretroviral Resistance: Mechanisms, Detection and Clinical Implications. Journal of Pharmacy Practice 13: 442-456 [Abstract]  
• Brown, A. J. L., Precious, H. M., Whitcomb, J. M., Wong, J. K., Quigg, M., Huang, W., Daar, E. S., D'Aquila, R. T., Keiser, P. H., Connick, E., Hellmann, N. S., Petropoulos, C. J., Richman, D. D., Little, S. J. (2000). Reduced Susceptibility of Human Immunodeficiency Virus Type 1 (HIV-1) from Patients with Primary HIV Infection to Nonnucleoside Reverse Transcriptase Inhibitors Is Associated with Variation at Novel Amino Acid Sites. J. Virol. 74: 10269-10273 [Abstract] [Full Text]  
• Beltrami, E. M., Williams, I. T., Shapiro, C. N., Chamberland, M. E. (2000). Risk and Management of Blood-Borne Infections in Health Care Workers. Clin. Microbiol. Rev. 13: 385-407 [Abstract] [Full Text]  
• Van Rompay, K. K. A., Miller, M. D., Marthas, M. L., Margot, N. A., Dailey, P. J., Canfield, D. R., Tarara, R. P., Cherrington, J. M., Aguirre, N. L., Bischofberger, N., Pedersen, N. C. (2000). Prophylactic and Therapeutic Benefits of Short-Term 9-[2-(R)-(Phosphonomethoxy)Propyl]Adenine (PMPA) Administration to Newborn Macaques following Oral Inoculation with Simian Immunodeficiency Virus with Reduced Susceptibility to PMPA. J. Virol. 74: 1767-1774 [Abstract] [Full Text]  
• Henry, K. (2000). The Case for More Cautious, Patient-Focused Antiretroviral Therapy. ANN INTERN MED 132: 306-311 [Abstract] [Full Text]  
• Boden, D., Hurley, A., Zhang, L., Cao, Y., Guo, Y., Jones, E., Tsay, J., Ip, J., Farthing, C., Limoli, K., Parkin, N., Markowitz, M. (1999). HIV-1 Drug Resistance in Newly Infected Individuals. JAMA 282: 1135-1141 [Abstract] [Full Text]  
• Little, S. J., Daar, E. S., D'Aquila, R. T., Keiser, P. H., Connick, E., Whitcomb, J. M., Hellmann, N. S., Petropoulos, C. J., Sutton, L., Pitt, J. A., Rosenberg, E. S., Koup, R. A., Walker, B. D., Richman, D. D. (1999). Reduced Antiretroviral Drug Susceptibility Among Patients With Primary HIV Infection. JAMA 282: 1142-1149 [Abstract] [Full Text]  
• Pomerantz, R. J. (1999). Primary HIV-1 Resistance: A New Phase in the Epidemic?. JAMA 282: 1177-1179 [Full Text]  
• Little, S. J., McLean, A. R., Spina, C. A., Richman, D. D., Havlir, D. V. (1999). Viral Dynamics of Acute HIV-1 Infection. JEM 190: 841-850 [Abstract] [Full Text]  
• Kashuba, A. D. M., Dyer, J. R., Kramer, L. M., Raasch, R. H., Eron, J. J., Cohen, M. S. (1999). Antiretroviral-Drug Concentrations in Semen: Implications for Sexual Transmission of Human Immunodeficiency Virus Type 1. Antimicrob. Agents Chemother. 43: 1817-1826 [Full Text]  
• García Lerma, J. G., Schinazi, R. F., Juodawlkis, A. S., Soriano, V., Lin, Y., Tatti, K., Rimland, D., Folks, T. M., Heneine, W. (1999). A Rapid Non-Culture-Based Assay for Clinical Monitoring of Phenotypic Resistance of Human Immunodeficiency Virus Type 1 to Lamivudine (3TC). Antimicrob. Agents Chemother. 43: 264-270 [Abstract] [Full Text]  
• Hecht, F. M., Grant, R. M., Petropoulos, C. J., Dillon, B., Chesney, M. A., Tian, H., Hellmann, N. S., Bandrapalli, N. I., Digilio, L., Branson, B., Kahn, J. O. (1998). Sexual Transmission of an HIV-1 Variant Resistant to Multiple Reverse-Transcriptase and Protease Inhibitors. NEJM 339: 307-311 [Full Text]  
• Cohen, O. J., Fauci, A. S. (1998). Transmission of Multidrug-Resistant Human Immunodeficiency Virus -- The Wake-Up Call. NEJM 339: 341-343 [Full Text]  
• Wainberg, M. A., Friedland, G. (1998). Public Health Implications of Antiretroviral Therapy and HIV Drug Resistance. JAMA 279: 1977-1983 [Abstract] [Full Text]  
• Hirsch, M. S., Conway, B., D'Aquila, R. T., Johnson, V. A., Brun-Vezinet, F., Clotet, B., Demeter, L. M., Hammer, S. M., Jacobsen, D. M., Kuritzkes, D. R., Loveday, C., Mellors, J. W., Vella, S., Richman, D. D., for the International AIDS Society-USA Panel, (1998). Antiretroviral Drug Resistance Testing in Adults With HIV Infection: Implications for Clinical Management. JAMA 279: 1984-1991 [Abstract] [Full Text]  
• Mayers, D. L. (1998). Drug-Resistant HIV-1: The Virus Strikes Back. JAMA 279: 2000-2002 [Full Text]  
• Bartlett, J. A. (1998). Strategies of Antiretroviral Therapy in Adults. The Oncologist 3: 111-118 [Abstract] [Full Text]  
• Quinn, T. C. (1997). Acute Primary HIV Infection. JAMA 278: 58-62 [Abstract]  
• Sinicco, A, Fora, R, Raiteri, R, Sciandra, M, Bechis, G, Calvo, M M, Gioannini, P (1997). Is the clinical course of HIV-1 changing? Cohort study. BMJ 314: 1232-1232 [Abstract] [Full Text]  
• Brown, A. J. L. (1997). Analysis of HIV-1 env gene sequences reveals evidence for a low effective number in the viral population. Proc. Natl. Acad. Sci. USA 94: 1862-1865 [Abstract] [Full Text]  
• Hu, D. J., Dondero, T. J., Rayfield, M. A., George, J. R., Schochetman, G., Jaffe, H. W., Luo, C.-C., Kalish, M. L., Weniger, B. G., Pau, C.-P., Schable, C. A., Curran, J. W. (1996). The Emerging Genetic Diversity of HIV: The Importance of Global Surveillance for Diagnostics, Research, and Prevention. JAMA 275: 210-216 [Abstract]  
• Forseter, G., Wormser, G. P., Joline, C. (1995). Is Zidovudine a Prophylactic Treatment for Health Care Workers?-Reply. Arch Intern Med 155: 1816-1817 [Abstract]  
• (1995). Antiretroviral Drug Resistance: Clinical Significance and Implications for HIV Pathogenesis. AIDS Clin Care 1995: 1-1 [Full Text]  
• Fitzgibbon, J. E., Gaur, S., Frenkel, L. D., Laraque, F., Edlin, B. R., Dubin, D. T. (1993). Transmission from One Child to Another of Human Immunodeficiency Virus Type 1 with a Zidovudine-Resistance Mutation. NEJM 329: 1835-1841 [Abstract] [Full Text]  
• Hermans, P., Sprecher, S., Clumeck, N., Masquelier, B., Lemoigne, E., Pellegrin, I., Douard, D., Sandler, B., Fleury, H. J.A., Erice, A., Balfour, H. H. (1993). Primary Infection with Zidovudine-Resistant HIV. NEJM 329: 1123-1124 [Full Text]  
• Bartlett, J. G. (1993). Zidovudine Now or Later?. NEJM 329: 351-352 [Full Text]  
• Vermund, S. H. (1993). Rising HIV-Related Mortality in Young Americans. JAMA 269: 3034-3035 [Abstract]  
• Hirsch, M. S., D'Aquila, R. T. (1993). Therapy for Human Immunodeficiency Virus Infection. NEJM 328: 1686-1695 [Full Text]  
• (1993). Zidovudine-Resistant HIV Strains Can Be Contagious. Journal Watch Dermatology 1993: 12-12 [Full Text]  
• Johnston, M., Hoth, D. (1993). Present status and future prospects for HIV therapies. Science 260: 1286-1293 [Abstract]  
• (1993). ZIDOVUDINE-RESISTANT HIV STRAINS CAN BE CONTAGIOUS. JWatch General 1993: 3-3 [Full Text]  
• Soeiro, R. (1993). A Tale of Two Mutants. NEJM 328: 1192-1193 [Full Text]  
• Garcia-Lerma, J. G., Nidtha, S., Blumoff, K., Weinstock, H., Heneine, W. (2001). From the Cover: Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons. Proc. Natl. Acad. Sci. USA 98: 13907-13912 [Abstract] [Full Text]